A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to help determine whether the addition of
Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in
vivo and vitro, when given along with temozolomide during the monthly cycles that follow
radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly
diagnosed high-grade glioma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Chinese Academy of Medical Sciences Fudan University Tianjin Medical University Cancer Institute and Hospital West China Hospital